
Meet The Professor: Optimizing the Management of Multiple Myeloma — Part 4 of a 4-Part Series
Hematologic Oncology Update
00:00
Is CAR T More Effective Than Silticell?
You know, the way things are right now, I think people are happy just as they get a slot with any CAR T. But we do have two approved products. And I am curious how you indirectly would compare both efficacy and tolerability of those two. Both of them are pretty well tolerated. We've seen a little more neurotoxicity with one of them, delayed neurot toxicity with cell to cell.
Transcript
Play full episode